Evaluation of the Pharmacokinetics of IPX237 Formulations in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
Price : $35 *
At a glance
- Drugs Esketamine (Primary) ; Esketamine (Primary) ; Esketamine
- Indications Depression
- Focus Pharmacokinetics
- Sponsors IMPAX Laboratories; Impax Pharmaceuticals
- 03 Jun 2014 Status changed from not yet recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
- 28 Nov 2013 Planned initiation date changed from 25 Nov 2013 to 9 Dec 2013 as reported by Australian New Zealand Clinical Trials Registry.
- 12 Nov 2013 New trial record